---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-110177"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:46:14.935353+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kezar halts lupus trial after 4 deaths; IDMC recommends stop

## Summary
- Voluntary cessation of enrollment and dosing in PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis.
- IDMC recommendation after review of 4 Grade 5 (fatal) serious adverse events in Philippines and Argentina.
- Three fatalities showed common symptom pattern and proximity to dosing; additional non-fatal SAEs with similar pattern.
- Kezar remains blinded to treatment arms; no prior deaths or serious opportunistic infections in earlier trials.
- PORTOLA trial in autoimmune hepatitis continues enrollment; no Grade 4 or 5 SAEs observed there to date.

## SEC filing metadata
- accession: 0000950170-24-110177
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017024110177/0000950170-24-110177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017024110177/kzr-20240930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-110177
- JSON: https://secwatch.observer/filing/0000950170-24-110177.json
- Plain text: https://secwatch.observer/filing/0000950170-24-110177.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.